
Christian M Seitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2643894/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The dual PI3K/mTOR inhibitor NVPâ€BEZ235 and chloroquine synergize to trigger apoptosis <i>via</i> mitochondrialâ€lysosomal crossâ€talk. International Journal of Cancer, 2013, 132, 2682-2693.	5.1	72
2	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications, 2021, 12, 7005.	12.8	66
3	Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports, 2018, 8, 16776.	3.3	59
4	GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncolmmunology, 2020, 9, 1683345.	4.6	54
5	Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncolmmunology, 2015, 4, e1014760.	4.6	49
6	CD34 ⁺ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. British Journal of Haematology, 2018, 180, 90-99.	2.5	39
7	Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. Oncolmmunology, 2020, 9, 1825177.	4.6	26
8	Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. Oncolmmunology, 2021, 10, .	4.6	16
9	CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. Briefings in Functional Genomics, 2020, 19, 191-200.	2.7	14
10	Combinatorial Targeting of Multiple Shared Antigens By Adapter-CAR-T Cells (aCAR-Ts) Allows Target Cell Discrimination and Specific Lysis Based on Differential Expression Profiles. Blood, 2018, 132, 4543-4543.	1.4	8
11	Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo. Annals of Hematology, 2015, 94, 1907-1919.	1.8	6
12	Ex vivo expansion of autologous, donor-derived NK-, γÎT-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity. Bone Marrow Transplantation, 2019, 54, 727-732.	2.4	5
13	Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2779-2791.	2.5	5
14	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. Bone Marrow Transplantation, 2019, 54, 689-693.	2.4	5
15	Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases. Cancers, 2021, 13, 1124.	3.7	5
16	Primary lung carcinoma in children and adolescents – Clinical characteristics and outcome of 12 cases from the German registry for rare paediatric tumours (STEP). Lung Cancer, 2021, 160, 66-72.	2.0	5
17	Adapter Chimeric Antigen Receptor (aCAR)-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Universal Tumor Targeting. Blood, 2018, 132, 3331-3331.	1.4	3
18	Rare Tumors in Children and Adolescents – the STEP Working Group's Evolution to a Prospective Registry. Klinische Padiatrie, 2022, 234, 146-153.	0.6	1

CHRISTIAN M SEITZ

#	Article	IF	CITATIONS
19	Recurrent SARS-CoV-2 Infection and Impaired Immunologic Response in a Pediatric Oncologic Patient While Treated With Radiochemotherapy. Pediatric Infectious Disease Journal, 2022, 41, e259-e262.	2.0	1
20	Abstract 658: Translational theranostic imaging of lymphoma using radiolabeled ${\rm \hat{l}\pm CD19}$ -antibodies. , 2018, , .		0
21	Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT. Blood, 2018, 132, 3388-3388.	1.4	Ο
22	Abstract A140: A T-cell utilizing bispecific anti-CD3/GD2 construct mediates superior in vitro efficacy compared to CH14.18 mAb in neuroblastoma patients after allogeneic SCT. , 2019, , .		0
23	Use of Ex Vivo Graft Manipulation and Posttransplant Cyclophosphamide Result in Low GvHD Rates and Acceptable Engraftment after RIC Regimens in Pediatric Mismatched SCT. Blood, 2019, 134, 3255-3255.	1.4	Ο
24	EPEN-09. Multi-omics characterization of the blood-brain barrier in molecular groups of ependymoma. Neuro-Oncology, 2022, 24, i40-i40.	1.2	0